Lake Street lowered the firm’s price target on Avita Medical (RCEL) to $3 from $4 and keeps a Hold rating on the shares. The firm remains on the sidelines until seeing sales stabilization and reacceleration and a more permanent financial solution to the balance sheet, the analyst tells investors in a post-earnings note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL: